Patents Examined by Taofiq A. Solola
  • Anxiolytic deuterated compound and medical use thereof
    Patent number: 11358944
    Abstract: The present invention provides compounds as represented by structural formula (I). In formula (I), R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 are separately H or deuterium (D) independently. Moreover, at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 must be D. Also provided is use of any of the compounds or its pharmaceutical composition in the preparation of a drug for treating an anxiety.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: June 14, 2022
    Assignee: BEIJING JUNKE HUAYUAN MED TECH CO., LTD.
    Inventors: Bohua Zhong, Jiajun Yang
  • Method for preparing cyclopenta[c]chromium compound
    Patent number: 11358945
    Abstract: The present invention discloses a method for preparing a cyclopenta[c]chromene compound. A cationic rare earth compound [Ln(CH)3CN)9]3+[(AlCl4)3]3?.CH3CN is used as a catalyst, and p-methyl thiophenol is used as an accelerator for a catalytic reaction of a chalcone compound so as to prepare a product; and Ln, contained in the catalyst, represents a positive trivalent rare earth metal ion and is selected from one of La, Nd, Sm, Gd and Yb. According to the method, the starting materials are easy to obtain, the reaction process is simple, the catalyst usage is low, the catalyst is universally applicable to various substituted 2-hydroxy chalcones, and the obtained cyclopenta[c]chromene compound has not been reported. The catalyst synthesis method is simple and easy to obtain, and the yield of the target product is high.
    Type: Grant
    Filed: January 31, 2021
    Date of Patent: June 14, 2022
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Fan Xu, Dandan Li, Xiaoyou Ding, Yanan Zhu, Zhigang Yao
  • Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same
    Patent number: 11352365
    Abstract: The present invention is directed to a compound having Formula (I) and its enantiomer: wherein the definitions of n, R, X, Y and Y3, and Z are provided in the disclosure. The invention is also directed to pharmaceutical compositions of the disclosed compounds, as well as their use as opioid-like agonists in the treatment of pain.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: June 7, 2022
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Kenner Cralle Rice, Arthur E. Jacobson, Fuying Li, Eugene S. Gutman, Eric W. Bow
  • Combination treatment of pancreatic cancer
    Patent number: 11351156
    Abstract: PI3K signalling is the most increased pathway in human cancers. The four isoforms of PI3K are thought to be activated by different redundant mechanisms leading to a common downstream signalling. The inventors questioned this concept, by mapping differential isoform-specific downstream signalling in response to their constant selective inhibition in pancreatic cancer, a disease currently without therapy. They identified common and specific signals activated by each PI3K isoform. These data make the rational for the development of highly selective PI3K isoform drugs used in combination, instead of compounds inhibiting all PI3Ks. In particular, the inventors showed that combined p110a and 110? inhibition is the most efficient strategy for pancreatic cancer patients.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: June 7, 2022
    Assignees: INSERM, Université Paul Sabatier Toulouse III, CNRS, Klinikum Rechts der Isar der Technischen Universität München
    Inventors: Julie Guillermet-Guibert, Maximillian Reichert, Célia Cintas
  • Imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-ones and the use thereof
    Patent number: 11345710
    Abstract: Disclosed are imidazo[1,2-b]pyrimido[4,5-d]pyridazin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R5 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: May 31, 2022
    Assignee: IMPACT THERAPEUTICS (SHANGHAI), INC
    Inventors: Suixiong Cai, Ye Edward Tian, Zhiqiang Dong, Xiaozhu Wang
  • Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
    Patent number: 11345677
    Abstract: Provided are solid forms of a compound useful for treating cancer, pharmaceutical compositions thereof, and methods of treating cancer comprising administering the solid forms described herein to a patient in need thereof.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: May 31, 2022
    Assignee: Servier Pharmaceuticals LLC
    Inventors: Benjamin S. Lane, Chong-Hui Gu
  • PI3KGAMMA inhibitors
    Patent number: 11344559
    Abstract: The present disclosure relates to PI3K? inhibitors and methods of their use.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: May 31, 2022
    Assignee: The Regents of the University of California
    Inventors: Judith Varner, Rommie Amaro, Megan Kaneda, Robert Malmstrom, Victoria Feher
  • Methods for treating, diagnosing and prognosing a haematological malignancy
    Patent number: 11337984
    Abstract: The invention relates to a serotonin receptor (5-HTR) inhibitor selected from the group consisting of a type 1 5-HTR inhibitor and a type 2 5-HTR inhibitor for use in the prevention and/or treatment of a haematological malignancy. Additionally, the invention relates to in vitro methods for the identification or isolation of a malignant cell from a haematological malignancy or for diagnosing a haematological malignancy based on detecting the expression of type 1 5-HTR and/or type 2 5-HTR. Furthermore, the invention relates to in vitro methods for determining the prognosis, for monitoring the effect of a therapy or for designing a customized therapy in a subject suffering from a haematological malignancy based on determining the levels of type 1 5-HTR and or type 2 5-HTR.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: May 24, 2022
    Assignee: Institut de Recerca Contra la Leucémia Josep Carreras
    Inventor: Ruth Muñoz Risueño
  • Medicinal use of serrulatane diterpenes
    Patent number: 11331299
    Abstract: The present disclosure is drawn to methods of treating diseases or disorders, and uses of preparing medicaments. The methods of administering and/or preparation of medicaments can include the use of a compound of Formula (I) disclosed herein, or a geometric isomer, stereoisomer, and/or pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: May 17, 2022
    Assignee: Kynan Duke IP, LLC
    Inventors: Colin Charles Duke, Rujee Kyokajee Duke, Van Hoan Tran
  • Method for producing halogenated N-arylpyrazoles
    Patent number: 11332447
    Abstract: The present invention relates to a process for preparing compounds of the formula (I) by halogenating compounds of the formula (II), where in R1, R2, R3 and X are defined according to the invention.
    Type: Grant
    Filed: May 20, 2019
    Date of Patent: May 17, 2022
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Rembiak, Eike Kevin Heilmann
  • Methods and compositions related to STK1-targeted small molecules as antibiotic resistance breakers
    Patent number: 11318141
    Abstract: Disclosed are methods and compositions related to STK1 inhibitors, such as Inh2-B1 (methyl 5-oxo-3-(phenyl carbamoyl)-1-thioxo-4,5dihydro[1,3]thiazolo[3,4-a]quinazoline-8-carboxylate). The STK1 inhibitors can act as an antibiotic resistance breakers against multidrug-resistant Staphylococcus aureus.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: May 3, 2022
    Assignee: Ohio State innovation Foundation
    Inventor: Vijay Pancholi
  • Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors
    Patent number: 11319324
    Abstract: The present invention covers substituted. Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: May 3, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Marcus Koppitz, Holger Siebeneicher, Nico Bräuer, Elisabeth Pook, Andrea Rotgeri, Roland Neuhaus, Oliver Martin Fischer, Jens Nagel, Adam James Davenport, James Lindsay Carr, Robert James Townsend, Nina Connelly Ursinyova, Shelley Anne Parrott
  • PIM kinase inhibitor compositions, methods, and uses thereof
    Patent number: 11319320
    Abstract: This application relates to compounds of formulae (I) and (II) and compositions thereof useful as inhibitors of PIM kinases. Also provided are methods of synthesis and methods of use of PIM inhibitors in treating individuals suffering from cancerous malignancies.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: May 3, 2022
    Assignee: SNAP BIO, INC.
    Inventors: Mark J. Burk, Brandon Chen, Jingyi Li, Shawn Bachan
  • (Hetero)arylamide compound for inhibiting protein kinase activity
    Patent number: 11319317
    Abstract: Provided are a (hetero)arylamide compound as shown in formula (I) having an inhibitory effect on protein kinase activity, a pharmaceutically acceptable salt, a stereoisomer, a solvate or hydrate thereof, a pharmaceutical composition including the compound or a derivative thereof, and a method for preparing the compound. The compound can be used as an irreversible inhibitor for protein kinase, for preparing a plurality of drugs including an anti-tumour drug.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: May 3, 2022
    Assignee: Shenzhen TargetRx, Inc.
    Inventors: Yihan Wang, Jiuyang Zhao, Yixin Ai
  • Treatment for cellulitis and pre-operative treatment
    Patent number: 11311550
    Abstract: A composition for the treatment of cellulitis is provided that includes an antibiotic. The composition may also include an analgesic, an anaesthetic, or a combination thereof. A method use is also provided by which the composition is applied topically or to affected skin. A method of use is also provided prior to a medical procedure involving an incision through the skin of a patient in a predetermined area, the method including the application, to the predetermined area and prior to the procedure of the composition.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: April 26, 2022
    Assignees: Multimode Medical Holdings Inc.
    Inventors: Patrick Musitano, Paul Zalzal
  • Combination of small molecule CD-47 inhibitors with other anti-cancer agents
    Patent number: 11311517
    Abstract: The present invention relates to a composition of a CD47-SIRP? blocking agent and one or more anti-cancer agent(s), where the CD47-SIRP? blocking agents are represented by a compound of formula (I). The present invention also relates to a method of treating a cancer in a subject by administering a therapeutically effective amount of a CD47-SIRP? blocking agent represented by formula (I) in combination with one or more anti-cancer agent(s).
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: April 26, 2022
    Assignee: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
    Inventors: Muralidhara Ramachandra, Pottayil Govindan Nair Sasikumar, Girish Chandrappa Daginakatte, Kiran Aithal Balkudru
  • Synthesis of morin and morin derivatives
    Patent number: 11312696
    Abstract: The invention relates to a method for directly producing morin derivatives and high-purity morin of formula (I). The invention also relates to morin derivatives and high-purity morin that can be obtained using the claimed method.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: April 26, 2022
    Assignee: ORSATEC GMBH
    Inventors: Thomas Lindel, Steffen Mende
  • Synthetic base and associated methods
    Patent number: 11311036
    Abstract: Glycine is an organic compound that can be used in the making of a synthetic base that obviates all the drawbacks of strong bases such as sodium hydroxide. The new compound is made by dissolving glycine in water and adding calcium hydroxide at a molar ration of about 1:1. Next, sodium percarbonate is dissolved in the solution to produce the new compound, which can be referred to as glycine hydroxide.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: April 26, 2022
    Assignee: Green Products & Technologies, L.L.C.
    Inventor: John T. MacDonald
  • Compositions and methods for restoring epidermal integrity and function and treating dermatological diseases
    Patent number: 11312725
    Abstract: Novel isohexide esters and isohexide compositions are prepared and used in improving skin health and condition.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: April 26, 2022
    Assignee: Sytheon Limited
    Inventor: Ratan K Chaudhuri
  • Methods of diagnosing and treating Tourette syndrome
    Patent number: 11298347
    Abstract: Methods and uses for diagnosing and treating Tourette syndrome are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.
    Type: Grant
    Filed: March 4, 2020
    Date of Patent: April 12, 2022
    Assignee: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
    Inventors: Hakon Hakonarson, Charlly Kao